Ratings Croda International Plc OTC Markets

Equities

COIH.Y

US2270473059

End-of-day quote OTC Markets Other stock markets 23:00:00 27/06/2024 BST			5-day change	1st Jan Change
24.84 ^USD	-1.90%		-3.72%	-25.36%

10:26am	Berenberg raises Centrica; UBS likes Rentokil	AN
10:00am	Spirax says Burdett to take on CFO post next week	AN

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company benefits from high valuations in earnings multiples.
With an enterprise value anticipated at 3.53 times the sales for the current fiscal year, the company turns out to be overvalued.
The valuation of the company is particularly high given the cash flows generated by its activity.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Sector: Specialty Chemicals

	1st Jan change	Capi.	ESG Refinitiv
CRODA INTERNATIONAL PLC	-25.36%	6.96B	-
ECOLAB INC.	+20.62%	67.97B	A-
SIKA AG	-6.43%	45.92B	A-
GIVAUDAN SA	+23.11%	43.74B	B+
FUJIFILM HOLDINGS CORPORATION	+32.85%	28.16B	A-
EMS-CHEMIE HOLDING AG	+8.37%	19.17B	C+
CELANESE CORPORATION	-12.92%	14.73B	B+
POSCO FUTURE M CO., LTD.	-27.99%	14.52B	A-
SOCIEDAD QUÍMICA Y MINERA DE CHILE S.A.	-31.52%	11.64B	A-
ALBEMARLE CORPORATION	-33.97%	11.23B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes